Literature DB >> 21384469

Distress in partners of individuals diagnosed with or at high risk of developing tumors due to rare hereditary cancer syndromes.

C R M Lammens1, E M A Bleiker, S Verhoef, M G E M Ausems, D Majoor-Krakauer, R H Sijmons, F J Hes, E B Gómez-García, T A M Van Os, L Spruijt, R B van der Luijt, A M W van den Ouweland, M W G Ruijs, C Gundy, T Nagtegaal, N K Aaronson.   

Abstract

OBJECTIVE: Li Fraumeni syndrome (LFS) and Von Hippel-Lindau disease (VHL) are two rare hereditary tumor syndromes, characterized by a high risk of developing multiple tumors at various sites and ages for which preventive and treatment options are limited. For partners, it may be difficult to deal with the on-going threat of tumors in both their spouse and children. Therefore, this study aims to evaluate the prevalence of and factors associated with psychological distress among partners of individuals with or at high risk of LFS or VHL.
METHODS: As part of a nationwide, cross-sectional study, partners of individuals diagnosed with or at high risk of LFS or VHL were invited to complete a self-report questionnaire assessing distress, worries, and health-related quality of life.
RESULTS: Fifty-five (58%) of those high-risk individuals with a partner consented to having their partner approached for the study. In total, 50 partners (91%) completed the questionnaire, of whom 28% reported clinically relevant levels of syndrome-related distress. Levels of distress and worries of the partners and their high-risk spouse were significantly correlated. Younger age and a lack of social support were also associated significantly with heightened levels of distress and worries. The majority of partners (76%) believed that professional psychosocial support should be routinely offered to them.
CONCLUSIONS: Approximately one-quarter of the partners exhibit clinically relevant levels of distress that warrant psychological support. The distress levels of the 'patient' could potentially be used to identify partners at risk of developing clinically relevant levels of distress.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21384469     DOI: 10.1002/pon.1951

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  14 in total

1.  Next generation sequencing is informing phenotype: a TP53 example.

Authors:  R O'Shea; R Clarke; E Berkley; C Giffney; M Farrell; E O'Donovan; D J Gallagher
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

2.  The Future of Surveillance in the Context of Cancer Predisposition: Through the Murky Looking Glass.

Authors:  David Malkin; Kim E Nichols; Joshua D Schiffman; Sharon E Plon; Garrett M Brodeur
Journal:  Clin Cancer Res       Date:  2017-11-01       Impact factor: 12.531

3.  Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes.

Authors:  Kelly L Stratton; Shaheen Alanee; Emily A Glogowski; Kasmintan A Schrader; Rohini Rau-Murthy; Robert Klein; Paul Russo; Jonathan Coleman; Kenneth Offit
Journal:  Urol Oncol       Date:  2015-12-23       Impact factor: 3.498

4.  Easing the Burden: Describing the Role of Social, Emotional and Spiritual Support in Research Families with Li-Fraumeni Syndrome.

Authors:  June A Peters; Regina Kenen; Renee Bremer; Shannon Givens; Sharon A Savage; Phuong L Mai
Journal:  J Genet Couns       Date:  2015-11-30       Impact factor: 2.537

5.  Disclosure of genetic risk to dating partners among young adults with von Hippel-Lindau disease.

Authors:  Elysa Bond; Beverly Yashar; Tobias Else; Jenae Osborne; Monica Marvin
Journal:  Fam Cancer       Date:  2022-08-19       Impact factor: 2.446

6.  TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.

Authors:  J J Bakhuizen; F B Hogervorst; M E Velthuizen; M W Ruijs; K van Engelen; T A van Os; J J Gille; M Collée; A M van den Ouweland; C J van Asperen; C M Kets; A R Mensenkamp; E M Leter; M J Blok; M M de Jong; M G Ausems
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

7.  A Novel von Hippel Lindau Gene Intronic Variant and Its Reclassification from VUS to Pathogenic: the Impact on a Large Family.

Authors:  A Sexton; L Rawlings; G McKavanagh; K Simons; I Winship
Journal:  J Genet Couns       Date:  2015-09-02       Impact factor: 2.537

Review 8.  Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.

Authors:  April D Sorrell; Carin R Espenschied; Julie O Culver; Jeffrey N Weitzel
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

9.  Psychological impact of von Hippel-Lindau genetic screening in patients with a previous history of hemangioblastoma of the central nervous system.

Authors:  Claire Rochette; Karine Baumstarck; Hélène Canoni-Zattara; Ahmad Esmaeel Abdullah; Dominique Figarella-Branger; Morgane Pertuit; Anne Barlier; Frédéric Castinetti; Karel Pacak; Philippe Metellus; David Taïeb
Journal:  J Psychosoc Oncol       Date:  2018-05-15

10.  Through the looking glass: an exploratory study of the lived experiences and unmet needs of families affected by Von Hippel-Lindau disease.

Authors:  Nadine A Kasparian; Alison Rutstein; Ursula M Sansom-Daly; Shab Mireskandari; Janet Tyler; Jessica Duffy; Katherine M Tucker
Journal:  Eur J Hum Genet       Date:  2014-04-02       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.